Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Uremic encephalopathy(UE) is the leading cause of emergency hemodialysis (HD) in patients with Kidney Failure, significantly impacting patient morbidity and mortality. Understanding the epidemiology, associated factors, and outcomes of kidney failure patients presenting with UE is crucial for developing preventive and management strategies. This study aimed to assess the prevalence, associated factors, and outcomes of incident HD patients presenting with UE compared to those without in two hospitals of different categories of health care in Cameroon (Buea Regional Hospital (BRH) and the Douala General Hospital (DGH)).
This retrospective cohort study analysed records of incident HD patients at the BRH and the DGH from January 2019 to December 2023 to determine the prevalence of UE. In this study, UE was defined as subtle to severe neurologic symptoms presenting with a diagnosis made by a nephrologist, and resolution of these symptoms following HD, excluding confounders. Data on the demographics, comorbidities, and key laboratory parameters (urea, creatinine, electrolytes) were extracted to assess associated factors. Continuous variables were summarised by their means and standard deviations, while categorical variables were presented as frequencies and proportions. Group comparisons used t-tests, Chi-square or Fisher’s Exact tests, and logistic regression identified significant associations (p < 0.05). Patients were grouped into UE and non-UE cohorts, and clinical outcomes were compared across these groups. The outcomes measured included the length of hospital stay at HD initiation and the 6-month mortality following initiation. Mortality status was assessed from hospital death records and phone contacts with the patient and their caregivers. The Kaplan-Meier Survival Analysis was used to assess the survival status of patients from the date of HD initiation to the date of death or the date of last follow-up.
Out of the 329 records included in this study, 69 had UE giving a prevalence of (20.9%). The factors associated with UE were older age (mean=49.7 years in UE vs 44.9 years in non-UE, p=0.017, OR=1.023) and higher serum urea levels (mean=255 mg/dl in UE vs 214 mg/dl, p=0.005, OR=1.004). Kidney failure patients presenting with UE have the highest six-month mortality rate of 56.5% (p=<0.001, OR=3.45). The Kaplan–Meier survival analysis, showed that patients with UE had a consistently lower survival compared to those without, with this difference becoming more pronounced over time.
Results from this study provide key insight into the clinical burden and prognostic significance of UE among patients newly initiated on HD. By identifying associated factors and outcome disparities, this research fills a notable gap in knowledge and reinforces the need for early recognition and timely intervention.
